BALAXI PHARMACEUTICALS
|
BALAXI PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 50.82 | 48.18 | 37.23 | 6.10 | 6.47 |
| CEPS(Rs) | 46.87 | 48.17 | 38.44 | 6.11 | 6.48 |
| DPS(Rs) | - | 0.50 | - | - | - |
| Book NAV/Share(Rs) | 169.51 | 113.16 | 64.98 | 27.75 | 11.58 |
| Tax Rate(%) | 19.25 | 12.59 | 13.97 | 30.59 | 19.41 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.07 | 18.19 | 18.45 | 18.09 | 11.46 |
| EBIT Margin(%) | 17.33 | 19.79 | 19.28 | 19.38 | 17.96 |
| Pre Tax Margin(%) | 16.92 | 19.51 | 19.16 | 19.27 | 17.94 |
| PAT Margin (%) | 13.66 | 17.06 | 16.49 | 13.38 | 14.46 |
| Cash Profit Margin (%) | 14.18 | 17.24 | 16.61 | 13.39 | 14.49 |
| Performance Ratios | |||||
| ROA(%) | 22.09 | 34.52 | 56.23 | 29.01 | 32.19 |
| ROE(%) | 32.17 | 53.50 | 82.26 | 39.04 | 55.84 |
| ROCE(%) | 37.46 | 59.62 | 92.56 | 56.56 | 69.35 |
| Asset Turnover(x) | 1.62 | 2.02 | 3.41 | 2.17 | 2.23 |
| Sales/Fixed Asset(x) | 9.18 | 17.32 | 157.71 | 461.40 | 1,203.13 |
| Working Capital/Sales(x) | 2.40 | 3.59 | 3.92 | 1.71 | 4.26 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.11 | 0.06 | 0.01 | - | - |
| Receivable days | 43.31 | 68.14 | 84.00 | 140.73 | 146.96 |
| Inventory Days | 110.51 | 73.37 | 11.40 | 6.66 | - |
| Payable days | 75.41 | 69.04 | 31.52 | 38.51 | 74.17 |
| Valuation Parameters | |||||
| PER(x) | 10.44 | 7.30 | 14.09 | 12.12 | 5.88 |
| PCE(x) | 11.32 | 7.30 | 13.65 | 12.11 | 5.87 |
| Price/Book(x) | 3.13 | 3.11 | 8.07 | 2.67 | 3.28 |
| Yield(%) | - | 0.14 | - | - | - |
| EV/Net Sales(x) | 1.56 | 1.25 | 2.28 | 1.53 | 0.84 |
| EV/Core EBITDA(x) | 8.72 | 6.24 | 11.72 | 7.91 | 4.67 |
| EV/EBIT(x) | 8.98 | 6.30 | 11.80 | 7.92 | 4.68 |
| EV/CE(x) | 2.18 | 1.97 | 5.28 | 1.95 | 1.87 |
| M Cap / Sales | 1.60 | 1.26 | 2.27 | 1.62 | 0.85 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 20.42 | 20.77 | 406.95 | 235.65 | - |
| Core EBITDA Growth(%) | 7.63 | 24.25 | 407.44 | 261.92 | - |
| EBIT Growth(%) | 5.46 | 23.93 | 404.51 | 262.13 | - |
| PAT Growth(%) | -3.56 | 24.96 | 524.83 | 210.47 | - |
| EPS Growth(%) | 5.48 | 29.41 | 510.03 | -5.62 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.07 | 0.03 | 0.06 | - | - |
| Current Ratio(x) | 3.64 | 2.23 | 2.70 | 4.24 | 2.23 |
| Quick Ratio(x) | 1.67 | 0.67 | 2.31 | 4.14 | 2.23 |
| Interest Cover(x) | 42.33 | 72.69 | 160.34 | 184.97 | 1,061.57 |
| Total Debt/Mcap(x) | 0.02 | 0.01 | 0.01 | - | - |
Compare Financial Ratios of peers of BALAXI PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BALAXI PHARMACEUTICALS | ₹632.9 Cr | 0.1% | 13.1% | 7.2% | Stock Analytics | |
| ADANI ENTERPRISES | ₹355,270.0 Cr | 3% | 1.7% | 68.8% | Stock Analytics | |
| REDINGTON | ₹17,445.3 Cr | 1.9% | 10.3% | 30.3% | Stock Analytics | |
| HONASA CONSUMER | ₹13,707.4 Cr | 9.6% | 14.7% | NA | Stock Analytics | |
| MMTC | ₹11,203.5 Cr | 5.3% | 13.2% | 159.8% | Stock Analytics | |
| MSTC | ₹6,532.4 Cr | 9% | 8.4% | 224.3% | Stock Analytics | |
BALAXI PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BALAXI PHARMACEUTICALS | 0.1% |
13.1% |
7.2% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
